Antibacterial Drugs Market

Antibacterial Drugs Market (Drug Class - B - lactams, Quinolones, Macrolides, Tetracycline, Aminoglycoside, Sulfonamide, and Phenicols; Routes of Administration - Enteral and Parenteral; Distribution Channel - Hospital Pharmacies, Drug Stores and Retail Pharmacies, and Online Sales) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2019 - 2027

  • According to Transparency Market Research’s latest report on the global antibacterial drugs market for the historical period 2017–2018 and forecast period 2019–2027, high prevalence of infectious diseases, increase in research and developmental activities, and increase in initiatives by government in healthcare sector are the factors projected to drive the global market during the forecast period
  • According to the report, the global antibacterial drugs market was valued at US$ 46.37 Bn in 2018 and is anticipated to expand at a CAGR of 1.5% from 2019 to 2027
fa global antibacterial drugs market

To know the scope of our report Get a Sample on Antibacterial Drugs Market 

Increase in Prevalence of Infectious Diseases: Key Driver

  • High prevalence of infectious diseases results in increasing number of patient population and rise in the demand for antibacterial drugs, which thereby is responsible for driving the antibacterial drugs market
  • According to Baylor College of Medicine, infectious diseases are a leading cause of death worldwide, particularly in low income countries, especially in young children.
  • European Centre for Disease Prevention and Control (ECDC) states that, every year, around three million people in the EU catch a healthcare-associated infection, of whom approximately 50,000 die.
  • According to National Hospital Ambulatory Medical Care Survey in 2016 in U.S., approximately 280,000, emergency department visits resulted in hospital admission with a principal hospital discharge diagnosis of infectious and parasitic diseases

Get a glimpse of the in-depth analysis through our Report Brochure

Increase in geriartic population and increasing number of antibiotic resistance or multi-drug resistant bacterial strains

  • According to a study published in 2016, titled “Infection in an aging population”, the global population is rapidly aging. Currently, 566 million people are 65 years old worldwide, with estimates of nearly 1.5 billion by 2050, particularly in developing countries. Infections constitute a third of mortality in people 65 years old. Moreover, lengthening life spans correlate with increased time in hospitals or long-term care facilities and exposure to drug-resistant pathogens. Indeed, the risk of nosocomial infections increases with age, independent of duration spent in healthcare facilities.
  • According to WHO, antibiotic resistant bacteria are responsible for up to 60% of hospital acquired infections in the United States. Resistance means that people with infections are ill for longer periods, and are at greater risk of dying, and that disease epidemics are prolonged.
  • As per WHO, in 2016, around 490,000 people developed multi-drug resistant tuberculosis globally, and drug resistance is starting to complicate the fight against HIV and malaria, as well.
  • Therefore, rise in geriatric population, and increasing number of antibiotic resistance or multi-drug resistant bacterial strains are responsible for boosting the growth of the antibacterial drugs market

Rising number of generic drugs for antibacterial activities and patent expiries to Hamper Market

  • The Generic Drug User Fee Amendments (GDUFA), passed by U.S. Congress in 2012, were intended to speed U.S. Food and Drug Administration approval of new generic drugs, which create competition for brand drugs and reduce drug prices for consumers.
  • Wide availability of over the counter (OTC) drugs and generic drugs, and number of antibacterial drugs near to off patent is anticipated to lead to a shift from branded drugs to generic ones, which could hamper the antibacterial drugs market from realizing its true revenue potential.
  • Henceforth, above mentioned factors can thereby hamper the growth of the market

Expanding operations in future? To get the perfect launch ask for a custom report 

Competitive Landscape

  • This report profiles major players in the global antibacterial drugs market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments
  • The global market is highly fragmented, with the presence of a number of international as well as regional players
  • Leading players operating in the global antibacterial drugs industry are
    • Bayer AG
    • Pfizer Inc.
    • Sanofi
    • GlaxoSmithKline plc.
    • Merck & Co., Inc.
    • AstraZeneca
    • Johnson & Johnson Services, Inc.
    • Bristol-Myers Squibb Company
    • Novartis AG
    • Allergan, 

Key Developments

Key players in the global antibacterial drugs market are engaged in regulatory approvals, new drug developemnt, launch of new products, and acquisition & collaborative agreements with other companies. These strategies are likely to fuel the growth of the market. A few expansion strategies adopted by players operating in the global antibacterial drugs market are:

  • In October 2019, GSK started a phase III clinical programme for a potential first-in-class antibiotic, gepotidacin
  • In July 2019, the FDA approved new triple-drug antibiotic from Merck, Recarbrio (imipenem, cilastatin, relebactam) for injection, 1.25 gm for the treatment of patients at least 18 years old with complicated urinary tract infections, including pyelonephritis, and complicated intra abdominal infections caused by certain Gram-negative bacteria who have limited or no alternative treatment options.
  • In August 2016, Pfizer Inc. announced that it has entered into an agreement with AstraZeneca to acquire the development and commercialization rights to its late-stage small molecule anti-infectives business, primarily outside the United States.

The report on the global market discussed individual strategies, followed by company profiles of manufacturers of antibacterial drugs. The competitive landscape section has been included in the report to provide readers with a dashboard view and a company market share analysis of key players operating in the global antibacterial drugs market.

Global Antibacterial drugs Market – Segmentation

Drug Class

B-lactam

Quinolones

Macrolides

Tetracyclines

Aminoglycosides

Sulfonamides

Phenicols

Others

Route of Administration

Enteral

Parenteral

Others

Distribution Channel

Hospital Pharmacies

Drug Stores and Retail Pharmacies

Online Sales

Region

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

Frequently Asked Questions

How big will be the global antibacterial drugs market in 2018?

it was valued at US$ 46.37 Bn in 2018

What is the anticipated CAGR of the market in the forecast period?

It is anticipated to expand at a CAGR of 1.5% from 2019 to 2027

What are the key driving factors for the growth of the market?

Antibacterial drugs market is driven by increase in prevalence of infectious diseases

Who are the key players in the antibacterial drugs industry?

Bayer AG, Pfizer Inc., Sanofi, GlaxoSmithKline plc., Merck & Co., Inc.

    Chapter 1. Preface

        1.1. Report Scope and Market Segmentation 

        1.2. Research Highlights

        1.3. Assumptions and Acronyms Used

    Chapter 2. Research Methodology 

    Chapter 3.  Executive Summary 

    Chapter 4. Market Overview

        4.1. Product Overview

        4.2. Key Industry Developments 

        4.3. Market Dynamics 

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunity Analysis

            4.3.4. Porter’s Five Forces Representation

            4.3.5. Antibacterial Drugs Market- Value Chain Analysis & Supply-Demand Scenario

            4.3.6. Antibacterial Drugs Market Outlook

            4.3.7. Anti-Bacterial Drugs Pipeline Analysis 

    Chapter 5. Global Antibacterial Drugs Market Analysis, by Drug Class, 2017 – 2027

        5.1. Key Findings

        5.2.  Definition

        5.3. Introduction

        5.4. Global Antibacterial Drugs Market Value Share Analysis, by Drug Class, 2018 and 2027

        5.5. Global Antibacterial Drugs Market Analysis, by Drug Class

            5.5.1. β-lactam 

            5.5.2. Quinolones

            5.5.3. Macrolides

            5.5.4. Tetracycline

            5.5.5. Aminoglycoside

            5.5.6. Sulfonamide

            5.5.7. Phenicols

            5.5.8. Others

        5.6. Global Antibacterial Drugs Market Attractiveness Analysis, by Drug Class

        5.7. Global Antibacterial Drugs Market Forecast, by Drug Class

        5.8. Key Trends

    Chapter 6. Global Antibacterial Drugs Market Analysis, by Routes of Administration 

        6.1. Key Findings

        6.2. Definitions

        6.3. Introduction

        6.4. Global Antibacterial Drugs Market Value Share Analysis, by Routes of Administration, 2018 and 2027

        6.5. Global Antibacterial Drugs Market Analysis, by Routes of Administration

            6.5.1. Enteral

            6.5.2. Parenteral

            6.5.3. Others 

        6.6.  Antibacterial Drugs Market Attractiveness Analysis, by Routes of Administration

        6.7. Global Antibacterial Drugs Market Forecast, by Routes of Administration

    Chapter 7. Global Antibacterial Drugs Market Analysis, by Channels of Distribution 

        7.1.  Key Findings

        7.2. Definitions

        7.3. Introduction 

        7.4. Global Antibacterial Drugs Market Value Share Analysis, by Channels of Distribution, 2018 and 2027

        7.5. Global Antibacterial Drugs Market Analysis, by Channels of Distribution

            7.5.1. Hospital Pharmacies

            7.5.2. Drug Stores & Retail Pharmacies

            7.5.3. Online Sales

        7.6. Global Antibacterial Drugs Market Attractiveness Analysis, by Channels of Distribution

        7.7. Global Antibacterial Drugs Market Forecast, by Channels of Distribution

        7.8. Key Trends

    Chapter 8. Global Antibacterial Drugs Market Analysis, by Region

        8.1.  Key Findings 

        8.2. Introduction

        8.3. Global Antibacterial Drugs Market Value Share Analysis, by Region, 2018 and 2027

        8.4. Global Antibacterial Drugs Market Attractiveness Analysis, by Region

        8.5. Global Antibacterial Drugs Market Forecast, by Region, 2017–2027

    Chapter 9. North America Antibacterial Drugs Market Analysis

        9.1. North America Antibacterial Drugs Market Overview

        9.2. North America Antibacterial Drugs Market Forecast, Country wise, 2017–2027

        9.3. North America Antibacterial Drugs Market Value Share Analysis, by Drug Class, 2018 and 2027

        9.4. North America Antibacterial Drugs Market Attractiveness Analysis, by Drug Class

        9.5. North America Antibacterial Drugs Market Forecast, by Drug Class, 2017–2027

        9.6. North America Antibacterial Drugs Market Value Share Analysis, by Routes of Administration, 2018 and 2027

        9.7. North America Antibacterial Drugs Market Attractiveness Analysis, by Routes of Administration

        9.8. North America Antibacterial Drugs Market Forecast, by Routes of Administration, 2017–2027

        9.9. North America Antibacterial Drugs Market Value Share Analysis, by Channels of Distribution, 2018 and 2027

        9.10.  North America Antibacterial Drugs Market Attractiveness Analysis, by Channels of Distribution

        9.11.  North America Antibacterial Drugs Market Forecast, by Channels of Distributions, 2017–2027

        9.12.  Key Trends

    Chapter 10. Europe Antibacterial Drugs Market Analysis

        10.1.  Europe Antibacterial Drugs Market Overview

        10.2.  Europe Antibacterial Drugs Market Forecast, Country wise, 2017–2027

        10.3.  Europe Antibacterial Drugs Market Value Share Analysis, by Drug Class, 2018 and 2027

        10.4.  Europe Antibacterial Drugs Market Attractiveness Analysis, by Drug Class

        10.5.  Europe Antibacterial Drugs Market Forecast, by Drug Class, 2017–2027

        10.6.  Europe Antibacterial Drugs Market Value Share Analysis, by Routes of Administration, 2018 and 2027

        10.7.  Europe Antibacterial Drugs Market Attractiveness Analysis, by Routes of Administration, 

        10.8.  Europe Antibacterial Drugs Market Forecast, by Routes of Administration, 2017–2027

        10.9.  Europe Antibacterial Drugs Market Value Share Analysis, by Channels of Distribution, 2018 and 2027

        10.10.  Europe Antibacterial Drugs Market Attractiveness Analysis, by Channels of Distribution 

        10.11.  Europe Antibacterial Drugs Market Forecast, by Channels of Distributions, 2017–2027

        10.12.  Key Trends

    Chapter 11.  Asia Pacific  Antibacterial Drugs Market Analysis

        11.1.  Asia Pacific  Antibacterial Drugs Market Overview

        11.2.  Asia Pacific  Antibacterial Drugs Market Forecast, Country wise, 2017–2027

        11.3.  Asia Pacific  Antibacterial Drugs Market Value Share Analysis, by Drug Class, 2018 and 2027

        11.4.  Asia Pacific  Antibacterial Drugs Market Attractiveness Analysis, by Drug Class

        11.5.  Asia Pacific  Antibacterial Drugs Market Forecast, by Drug Class, 2017–2027

        11.6.  Asia Pacific  Antibacterial Drugs Market Value Share Analysis, by Routes of Administration, 2018 and 2027

        11.7.  Asia Pacific  Antibacterial Drugs Market Attractiveness Analysis, by Routes of Administration

        11.8.  Asia Pacific  Antibacterial Drugs Market Forecast, by Routes of Administration, 2017–2027

        11.9.  Asia Pacific  Antibacterial Drugs Market Value Share Analysis, by Channels of Distribution, 2018 and 2027

        1.1.  Pacific  Antibacterial Drugs Market Attractiveness Analysis, by Channels of Distribution 

        11.10. Asia Pacific Antibacterial Drugs Market Forecast, by Channels of Distributions, 2017–2027

        11.11. Key Trends

    Chapter 12.  Latin America  Antibacterial Drugs Market Analysis

        12.1.  Latin America  Antibacterial Drugs Market Overview

        12.2.  Latin America  Antibacterial Drugs Market Forecast, Country wise, 2017–2027

        12.3.  Latin America  Antibacterial Drugs Market Value Share Analysis, by Drug Class, 2018 and 2027

        12.4.  Latin America  Antibacterial Drugs Market Attractiveness Analysis, by Drug Class

        12.5.  Latin America  Antibacterial Drugs Market Forecast, by Drug Class, 2017–2027

        12.6.  Latin America  Antibacterial Drugs Market Value Share Analysis, by Routes of Administration, 2018 and 2027

        12.7.  Latin America  Antibacterial Drugs Market Attractiveness Analysis, by Routes of Administration

        12.8.  Latin America  Antibacterial Drugs Market Forecast, by Routes of Administration, 2017–2027

        12.9.  Latin America  Antibacterial Drugs Market Value Share Analysis, by Channels of Distribution, 2018 and 2027

        12.10.  Latin America Antibacterial Drugs Market Attractiveness Analysis, by Channels of Distribution

        12.11.  Latin America Antibacterial Drugs Market Forecast, by Channels of Distributions, 2017–2027

        12.12.  Key Trends

    Chapter 13.  Middle East & Africa Antibacterial Drugs Market Analysis

        13.1.  Middle East & Africa   Antibacterial Drugs Market Overview

        13.2.  Middle East & Africa   Antibacterial Drugs Market Forecast, Country wise, 2017–2027

        13.3.  Middle East & Africa  Antibacterial Drugs Market Value Share Analysis, by Drug Class, 2018 and 2027

        13.4.  Middle East & Africa  Antibacterial Drugs Market Attractiveness Analysis, by Drug Class

        13.5.  Middle East & Africa  Antibacterial Drugs Market Forecast, by Drug Class, 2017–2027

        13.6.  Middle East & Africa  Antibacterial Drugs Market Value Share Analysis, by Routes of Administration, 2018 and 2027

        13.7.  Middle East & Africa Antibacterial Drugs Market Attractiveness Analysis, by Routes of Administration

        13.8.  Middle East & Africa Antibacterial Drugs Market Forecast, by Routes of Administration, 2017–2027

        13.9.  Middle East & Africa Antibacterial Drugs Market Value Share Analysis, by Channels of Distribution, 2018 and 2027

        13.10. Middle East & Africa Antibacterial Drugs Market Attractiveness Analysis, by Channels of Distribution

        13.11.  Middle East & Africa Antibacterial Drugs Market Forecast, by Channels of Distributions, 2017–2027

        13.12.  Key Trends

    Chapter 14.  Competition Landscape

        14.1.  Leading Antibacterial Drugs Sales Analysis 

        14.2.  Competition Matrix

        14.3.  Company Profiles 

            14.3.1. Bayer AG

                14.3.1.1. Company Description

                14.3.1.2. Business Overview

                14.3.1.3. SWOT Analysis

                14.3.1.4. Strategic Overview

            14.3.2. Pfizer Inc.

                14.3.2.1. Company Description

                14.3.2.2. Business Overview

                14.3.2.3. SWOT Analysis

                14.3.2.4. Strategic Overview

            14.3.3. Sanofi

                14.3.3.1. Company Description

                14.3.3.2. Business Overview

                14.3.3.3. SWOT Analysis

                14.3.3.4. Strategic Overview

            14.3.4. GlaxoSmithKline plc

                14.3.4.1. Company Description

                14.3.4.2. Business Overview

                14.3.4.3. SWOT Analysis

                14.3.4.4. Strategic Overview

            14.3.5. Merck & Co., Inc.

                14.3.5.1. Company Description

                14.3.5.2. Business Overview

                14.3.5.3. SWOT Analysis

                14.3.5.4. Strategic Overview

            14.3.6. AstraZeneca

                14.3.6.1. Company Description

                14.3.6.2. Business Overview

                14.3.6.3. SWOT Analysis

                14.3.6.4. Strategic Overview

            14.3.7. Johnson and Johnson Services, Inc.

                14.3.7.1. Company Description

                14.3.7.2. Business Overview

                14.3.7.3. SWOT Analysis

                14.3.7.4. Strategic Overview

            14.3.8. Bristol-Myers Squibb Company

                14.3.8.1. Company Description

                14.3.8.2. Business Overview

                14.3.8.3. SWOT Analysis

                14.3.8.4. Strategic Overview

            14.3.9. Novartis AG

                14.3.9.1. Company Description

                14.3.9.2. Business Overview

                14.3.9.3. SWOT Analysis

                14.3.9.4. Strategic Overview

            14.3.10. Allergen 

                14.3.10.1. Company Description

                14.3.10.2. Business Overview

                14.3.10.3. SWOT Analysis

                14.3.10.4. Strategic Overview

    List of Table

    Table 01: Global Antibacterial Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017–2027

    Table 02: Global Antibacterial Drugs Market Size (US$ Mn) Forecast, by Routes of Administration, 2017–2027

    Table 03: Global Antibacterial Drugs Market Size (US$ Mn) Forecast, by Channels of Distribution, 2017–2027

    Table 04: Global Antibacterial Drugs Market Size (US$ Mn) Forecast, by Region, 2017–2027

    Table 05: North America Antibacterial Drugs Market Size (US$ Mn) Forecast, Country Wise, 2017–2027

    Table 06: North America Antibacterial Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017–2027

    Table 07: North America Antibacterial Drugs Market Size (US$ Mn) Forecast, by Routes of Administration,2017–2027

    Table 08: North America Antibacterial Drugs Market Size (US$ Mn) Forecast, by Channels of Distributions,2017–2027

    Table 09: Europe Antibacterial Drugs Market Size (US$ Mn) Forecast, Country Wise, 2017–2027

    Table 10: Europe Antibacterial Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017–2027

    Table 11: Europe Antibacterial Drugs Market Size (US$ Mn) Forecast, by Routes of Administration, 2017–2027

    Table 12: Europe Antibacterial Drugs Market Size (US$ Mn) Forecast, by Channels of Distribution, 2017–2027

    Table 13: Asia Pacific Antibacterial Drugs Market Size (US$ Mn) Forecast, Country Wise, 2017–2027

    Table 14: Asia Pacific Antibacterial Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017–2027

    Table 15: Asia Pacific Antibacterial Drugs Market Size (US$ Mn) Forecast, by Routes of Administration, 2017–2027

    Table 16: Asia Pacific Antibacterial Drugs Market Size (US$ Mn) Forecast, by Channels of Distribution, 2017–2027

    Table 17: Latin America Antibacterial Drugs Market Size (US$ Mn) Forecast, by Country Wise, 2017–2027

    Table 18: Latin America Antibacterial Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017–2027

    Table 19: Latin America Antibacterial Drugs Market Size (US$ Mn) Forecast, by Routes of Administration,2017–2027

    Table 20: Latin America Antibacterial Drugs Market Size (US$ Mn) Forecast, by Channels of Distribution, 2017–2027

    Table 21: Middle East & Africa Antibacterial Drugs Market Size (US$ Mn) Forecast, by Country Wise, 2017–2027

    Table 22: Middle East & Africa Antibacterial Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017–2027

    Table 23: MEA Antibacterial Drugs Market Size (US$ Mn) Forecast, by Routes of Administration, 2017–2027

    Table 24: MEA Antibacterial Drugs Market Size (US$ Mn) Forecast, by Channels of Distribution, 2017–202

    List of Figure

    Figure 01: Global Antibacterial Drugs Market Size ($ Mn) and Distribution by Geography, 2018 and 2027

    Figure 02: Global Antibacterial Drugs Market Revenue (US$ Mn) and top 3 trends  

    Figure 03: Global Antibacterial Drugs Market, by Channels of Distribution, Revenue (US$ Mn) and Market Share

    Figure 04: Market Value Share By Drug Class (2018) Revenue (US$ Mn)

    Figure 05: Market Value Share By Region (2018) Revenue (US$ Mn)

    Figure 06: Antibacterial Drugs in Clinical Trials 

    Figure 07: Anti-bacterial Drugs by Indication

    Figure 08: Anti-bacterial Drugs by class

    Figure 09: Global Antibacterial Drugs Market Value Share Analysis, by Drug Class, 2018 and 2027

    Figure 10: Global β-lactam Market Revenue (US$ Mn) and Y-o-Y Growth (%), by β-lactam, 2017–2027

    Figure 11: Global Quinolones Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2027

    Figure 12: Global Macrolides Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2027

    Figure 13: Global Tetracyclines Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2027

    Figure 14: Global Aminoglycosides Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2027

    Figure 15: Global Sulfonamides Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2027

    Figure 16: Global Phenicols Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2027

    Figure 17: Global Others Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2027

    Figure 18: Global Antibacterial Drugs Market Attractiveness Analysis, by Drug Class

    Figure 19: Global Antibacterial Drugs Market Value Share Analysis, by Routes of Administration, 2018 and 2027

    Figure 20: Global Enteral Segment Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2027

    Figure 21: Global Parenteral Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2027

    Figure 22: Global Others routes of administration Segment Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2027

    Figure 23: Global Antibacterial Drugs Market Attractiveness Analysis, by Routes od Administration

    Figure 24: Global Antibacterial Drugs Market Value Share Analysis, by Channels of Distribution, 2018 and 2027

    Figure 25: Global Hospital Pharmacies Segment Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2027

    Figure 26: Global Drug Stores & Retail Pharmacies Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2027

    Figure 27: Global Online Sales Segment Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2027

    Figure 28: Global Antibacterial Drugs Market Attractiveness Analysis, by Channels of Distribution

    Figure 29: Global Antibacterial Drugs Market Value Share Analysis, by Region, 2018 and 2027

    Figure 30: Global Antibacterial Drugs Market Attractiveness Analysis, by Region, 2018

    Figure 31: North America Antibacterial Drugs Market Size (US$ Mn) Forecast, 2017–2027

    Figure 32: North America Antibacterial Drugs Market Y-o-Y Growth Projections, 2017–2027

    Figure 33: North America Antibacterial Drugs Market Value Share Analysis, by Drug Class, 2018 and 2027

    Figure 34: North America Antibacterial Drugs Market Attractiveness Analysis, by Drug Class

    Figure 35: North America Antibacterial Drugs Market Value Share Analysis, by Routes of Administration, 2018 and 2027

    Figure 36: North America Antibacterial Drugs Market Attractiveness Analysis, by Routes of Administration

    Figure 37: North America Antibacterial Drugs Market Value Share Analysis, by Channels of Distribution, 2018 and 2027

    Figure 38: North America Antibacterial Drugs Market Attractiveness Analysis, by Channels of Distribution

    Figure 39: Europe Antibacterial Drugs Market Size (US$ Mn) Forecast, 2017–2027

    Figure 40: Europe Antibacterial Drugs Market Y-o-Y Growth Projections, 2017–2027

    Figure 41: Europe Antibacterial Drugs Market Value Share Analysis, by Drug Class, 2018 and 2027

    Figure 42: Europe Antibacterial Drugs Market Attractiveness Analysis, by Drug Class

    Figure 43: Europe Antibacterial Drugs Market Value Share Analysis, by Routes of Administration, 2018 and 2027

    Figure 44: Europe Antibacterial Drugs Market Attractiveness Analysis, by Routes of Administration

    Figure 45: Europe Antibacterial Drugs Market Value Share Analysis, by Channels of Distribution, 2018 and 2027

    Figure 46: Europe Antibacterial Drugs Market Attractiveness Analysis, by Distribution

    Figure 47: Asia Pacific Antibacterial Drugs Market Size (US$ Mn) Forecast, 2017–2027

    Figure 48: Asia Pacific Antibacterial Drugs Market Y-o-Y Growth Projections, 2017–2027

    Figure 49: Asia Pacific Antibacterial Drugs Market Value Share Analysis, by Drug Class, 2018 and 2027

    Figure 50: Asia Pacific Antibacterial Drugs Market Attractiveness Analysis, by Drug Class

    Figure 51: Asia Pacific Antibacterial Drugs Market Value Share Analysis, by Routes of Administration, 2018 and 2027

    Figure 52: Asia Pacific Antibacterial Drugs Market Attractiveness Analysis, by Routes of Administration

    Figure 53: Asia Pacific Antibacterial Drugs Market Value Share Analysis, by Channels of Distribution, 2018 and 2027

    Figure 54: Asia Pacific Antibacterial Drugs Market Attractiveness Analysis, by Distribution

    Figure 55: Latin America Antibacterial Drugs Market Size (US$ Mn) Forecast, 2017–2027

    Figure 56: Latin America Antibacterial Drugs Market, Y-o-Y Growth Projection, 2017–2027

    Figure 57: Latin America Antibacterial Drugs Market Value Share Analysis, by Drug Class, 2018 and 2027

    Figure 58: Latin America Antibacterial Drugs Market Attractiveness Analysis, by Drug Class

    Figure 59: Latin America Antibacterial Drugs Market Value Share Analysis, by Routes of Administration, 2018 and 2027

    Figure 60: Latin America Antibacterial Drugs Market Attractiveness Analysis, by Routes of Administration

    Figure 61: Latin America Antibacterial Drugs Market Value Share Analysis, by Channels of Distribution, 2018 and 2027

    Figure 62: Latin America Antibacterial Drugs Market Attractiveness Analysis, by Distribution

    Figure 63: Middle East & Africa Antibacterial Drugs Market Size (US$ Mn) Forecast, 2017–2027

    Figure 64: Middle East & Africa Antibacterial Drugs Market Y-o-Y Growth Projections, 2017–2027

    Figure 65: Middle East & Africa Antibacterial Drugs Market Value Share Analysis, by Drug Class, 2018 and 2027

    Figure 66: Middle East & Africa Antibacterial Drugs Market Attractiveness Analysis, by Drug Class

    Figure 67: MEA Antibacterial Drugs Market Value Share Analysis, by Routes of Administration, 2018 and 2027

    Figure 68: MEA Antibacterial Drugs Market Attractiveness Analysis, by Routes of Administration

    Figure 69: MEA Antibacterial Drugs Market Value Share Analysis, by Channels of Distribution, 2018 and 2027

    Figure 70: MEA Antibacterial Drugs Market Attractiveness Analysis, by Distribution

    Figure 71: Leading Antibacterial Drugs Sales Analysis, 2018

    Figure 72: Bayer AG, Breakdown of Net Sales, by Region, 2018

    Figure 73: Bayer AG, Revenue (US$ Mn) & Y-o-Y Growth (%), 2015–2018

    Figure 74: Pfizer, Breakdown of Net Sales, by Region, 2018

    Figure 75: Pfizer, Revenue (US$ Bn) & Y-o-Y Growth (%), 2015–2018

    Figure 76: Sanofi, Breakdown of Net Sales, by Region, 2018

    Figure 77: Sanofi, Revenue (US$ Bn) & Y-o-Y Growth (%), 2015–2018

    Figure 78: GlaxoSmithKline, Breakdown of Net Sales, by Region, 2018

    Figure 79: GlaxoSmithKline, Revenue (US$ Bn) & Y-o-Y Growth (%), 2015–2018

    Figure 80: Merck & Co., Breakdown of Net Sales, by Region, 2018

    Figure 81: Merck & Co., Revenue (US$ Mn) & Y-o-Y Growth (%), 2015–2018

    Figure 82: AstraZeneca, Breakdown of Net Sales, by Region, 2018

    Figure 83: AstraZeneca, Revenue (US$ Bn) & Y-o-Y Growth (%), 2015–2018

    Figure 84: Johnson & Johnson, Breakdown of Net Sales, by Region, 2016

    Figure 85: Johnson & Johnson, Revenue (US$ Bn) & Y-o-Y Growth (%), 2015–2018

    Figure 86: Bristol-Myers Squibb Company, Breakdown of Net Sales, by Region (2018)

    Figure 87: Bristol-Myers Squibb Company, Revenue (US$ Bn) & Y-o-Y Growth (%), 2015–2018

    Figure 88: Novartis AG, Breakdown of Net Sales, by Region, 2018

    Figure 89: Novartis AG, Revenue (US$ Bn) & Y-o-Y Growth (%), 2015–2018

    Figure 90: Allergen, Breakdown of Net Sales (%), by Segments (2018)

    Figure 91: Allergen, Revenue (US$ Bn) & Y-o-Y Growth (%), 2015–2018

Copyright © Transparency Market Research, Inc. All Rights reserved